Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 104 | 2022 | 9981 | 6.560 |
Why?
|
Brain Ischemia | 56 | 2022 | 3265 | 6.270 |
Why?
|
Periodicals as Topic | 11 | 2020 | 1432 | 2.470 |
Why?
|
Thrombectomy | 10 | 2022 | 680 | 2.460 |
Why?
|
Neuroprotective Agents | 17 | 2020 | 941 | 2.250 |
Why?
|
Endovascular Procedures | 11 | 2022 | 1979 | 2.240 |
Why?
|
Tissue Plasminogen Activator | 20 | 2018 | 1261 | 2.190 |
Why?
|
Thrombolytic Therapy | 20 | 2020 | 2161 | 2.000 |
Why?
|
Fibrinolytic Agents | 19 | 2020 | 2158 | 1.970 |
Why?
|
Editorial Policies | 4 | 2017 | 451 | 1.610 |
Why?
|
Infarction, Middle Cerebral Artery | 11 | 2020 | 475 | 1.570 |
Why?
|
Clinical Trials as Topic | 27 | 2018 | 7913 | 1.530 |
Why?
|
Cerebrovascular Disorders | 7 | 2018 | 1504 | 1.230 |
Why?
|
Cerebrovascular Circulation | 14 | 2019 | 2731 | 1.230 |
Why?
|
Reperfusion | 7 | 2022 | 284 | 0.960 |
Why?
|
Health Planning Guidelines | 4 | 2009 | 163 | 0.820 |
Why?
|
Diffusion Magnetic Resonance Imaging | 13 | 2019 | 2737 | 0.800 |
Why?
|
Atrial Fibrillation | 7 | 2020 | 5034 | 0.780 |
Why?
|
Review Literature as Topic | 2 | 2017 | 336 | 0.770 |
Why?
|
Intracranial Embolism | 4 | 2014 | 202 | 0.770 |
Why?
|
Ischemic Attack, Transient | 7 | 2020 | 935 | 0.730 |
Why?
|
Neurology | 6 | 2021 | 763 | 0.690 |
Why?
|
Academies and Institutes | 1 | 2021 | 317 | 0.670 |
Why?
|
Reperfusion Injury | 5 | 2016 | 1026 | 0.650 |
Why?
|
Research | 5 | 2020 | 1999 | 0.610 |
Why?
|
Foramen Ovale, Patent | 2 | 2018 | 223 | 0.580 |
Why?
|
Evidence-Based Medicine | 4 | 2017 | 3610 | 0.570 |
Why?
|
Arterial Occlusive Diseases | 1 | 2021 | 793 | 0.570 |
Why?
|
Anticoagulants | 8 | 2020 | 4599 | 0.560 |
Why?
|
Platelet Aggregation Inhibitors | 6 | 2017 | 3068 | 0.530 |
Why?
|
International Cooperation | 3 | 2019 | 1420 | 0.520 |
Why?
|
Disease Models, Animal | 18 | 2020 | 18029 | 0.500 |
Why?
|
Research Design | 8 | 2017 | 5987 | 0.480 |
Why?
|
Drug Design | 3 | 2010 | 1076 | 0.480 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2013 | 648 | 0.470 |
Why?
|
Intracranial Hemorrhages | 3 | 2018 | 855 | 0.450 |
Why?
|
Brain Infarction | 3 | 2013 | 299 | 0.440 |
Why?
|
Interdisciplinary Communication | 2 | 2020 | 950 | 0.440 |
Why?
|
Publishing | 1 | 2020 | 833 | 0.430 |
Why?
|
Biomedical Research | 6 | 2019 | 3309 | 0.410 |
Why?
|
Humans | 109 | 2022 | 744343 | 0.410 |
Why?
|
Magnetic Resonance Angiography | 4 | 2014 | 1442 | 0.410 |
Why?
|
Cooperative Behavior | 3 | 2018 | 1504 | 0.400 |
Why?
|
Treatment Outcome | 29 | 2022 | 63114 | 0.400 |
Why?
|
Patient Selection | 9 | 2018 | 4215 | 0.380 |
Why?
|
Freezing | 1 | 2011 | 303 | 0.380 |
Why?
|
Intracranial Thrombosis | 1 | 2011 | 113 | 0.360 |
Why?
|
Cytoprotection | 2 | 2022 | 210 | 0.360 |
Why?
|
Cerebral Infarction | 4 | 2012 | 1011 | 0.350 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2017 | 3255 | 0.350 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1956 | 0.340 |
Why?
|
Rats | 18 | 2017 | 24260 | 0.340 |
Why?
|
Time Factors | 23 | 2019 | 40075 | 0.340 |
Why?
|
Ticlopidine | 2 | 2006 | 899 | 0.330 |
Why?
|
Benzenesulfonates | 2 | 2006 | 169 | 0.330 |
Why?
|
Acute Disease | 13 | 2010 | 7149 | 0.330 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2008 | 242 | 0.320 |
Why?
|
Self-Evaluation Programs | 1 | 2007 | 29 | 0.320 |
Why?
|
Thrombophilia | 1 | 2010 | 305 | 0.310 |
Why?
|
Embolism | 2 | 2008 | 408 | 0.310 |
Why?
|
Circle of Willis | 1 | 2007 | 68 | 0.300 |
Why?
|
Warfarin | 3 | 2020 | 1496 | 0.300 |
Why?
|
Disability Evaluation | 2 | 2019 | 1827 | 0.280 |
Why?
|
Cardiology | 1 | 2018 | 1668 | 0.280 |
Why?
|
Nitrogen Oxides | 1 | 2006 | 129 | 0.280 |
Why?
|
Patient Care Team | 1 | 2018 | 2531 | 0.280 |
Why?
|
Rats, Sprague-Dawley | 11 | 2009 | 8301 | 0.280 |
Why?
|
Hyperoxia | 1 | 2008 | 262 | 0.280 |
Why?
|
Animals | 40 | 2021 | 168757 | 0.270 |
Why?
|
Rats, Wistar | 5 | 2020 | 1901 | 0.270 |
Why?
|
Free Radical Scavengers | 1 | 2006 | 216 | 0.260 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1439 | 0.260 |
Why?
|
Brain | 8 | 2022 | 26385 | 0.260 |
Why?
|
Organizations | 2 | 2021 | 170 | 0.250 |
Why?
|
Middle Cerebral Artery | 1 | 2006 | 264 | 0.250 |
Why?
|
Gadolinium | 1 | 2009 | 952 | 0.240 |
Why?
|
Cerebral Arteries | 1 | 2007 | 494 | 0.240 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2018 | 9959 | 0.240 |
Why?
|
Biomedical Technology | 1 | 2007 | 220 | 0.240 |
Why?
|
Secondary Prevention | 5 | 2018 | 1530 | 0.240 |
Why?
|
China | 3 | 2020 | 2248 | 0.230 |
Why?
|
Nerve Fibers | 1 | 2007 | 687 | 0.230 |
Why?
|
Magnetic Resonance Imaging | 13 | 2020 | 35421 | 0.230 |
Why?
|
Therapeutics | 1 | 2004 | 116 | 0.230 |
Why?
|
Plaque, Atherosclerotic | 1 | 2015 | 1519 | 0.220 |
Why?
|
Device Approval | 1 | 2005 | 163 | 0.220 |
Why?
|
Choice Behavior | 1 | 2008 | 803 | 0.210 |
Why?
|
Tomography, X-Ray Computed | 5 | 2020 | 20129 | 0.200 |
Why?
|
Hypothermia | 1 | 2003 | 189 | 0.200 |
Why?
|
Recombinant Proteins | 5 | 2016 | 6622 | 0.200 |
Why?
|
Myocardial Infarction | 3 | 2018 | 11727 | 0.190 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2011 | 2915 | 0.190 |
Why?
|
Recovery of Function | 4 | 2019 | 2925 | 0.190 |
Why?
|
Cardiovascular Diseases | 3 | 2019 | 15165 | 0.190 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2002 | 339 | 0.180 |
Why?
|
Basilar Artery | 1 | 2021 | 200 | 0.180 |
Why?
|
Microspheres | 1 | 2003 | 777 | 0.180 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2005 | 1375 | 0.180 |
Why?
|
Aspirin | 2 | 2009 | 3282 | 0.170 |
Why?
|
Cerebral Hemorrhage | 3 | 2005 | 2647 | 0.160 |
Why?
|
Hemorrhage | 5 | 2019 | 3461 | 0.160 |
Why?
|
Perfusion Imaging | 1 | 2019 | 195 | 0.160 |
Why?
|
Drug Therapy, Combination | 5 | 2011 | 6489 | 0.150 |
Why?
|
Male | 39 | 2019 | 350118 | 0.150 |
Why?
|
Caspase 3 | 1 | 2020 | 758 | 0.150 |
Why?
|
Ischemic Preconditioning | 1 | 2017 | 92 | 0.150 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2010 | 3923 | 0.150 |
Why?
|
Quality Assurance, Health Care | 1 | 2007 | 2212 | 0.150 |
Why?
|
Homes for the Aged | 1 | 2019 | 260 | 0.140 |
Why?
|
Protein C | 1 | 2016 | 138 | 0.140 |
Why?
|
Medulla Oblongata | 1 | 2017 | 243 | 0.140 |
Why?
|
Contrast Media | 1 | 2009 | 5300 | 0.140 |
Why?
|
Disease Management | 2 | 2005 | 2459 | 0.140 |
Why?
|
Forecasting | 2 | 2015 | 2951 | 0.130 |
Why?
|
History, 21st Century | 2 | 2020 | 1534 | 0.130 |
Why?
|
Telemedicine | 4 | 2020 | 2872 | 0.130 |
Why?
|
Injections, Intravenous | 3 | 2009 | 1420 | 0.130 |
Why?
|
Nursing Homes | 2 | 2020 | 1036 | 0.130 |
Why?
|
Histone Deacetylases | 1 | 2020 | 728 | 0.130 |
Why?
|
Heparin | 1 | 2002 | 1637 | 0.130 |
Why?
|
Endpoint Determination | 2 | 2008 | 601 | 0.120 |
Why?
|
Stem Cell Transplantation | 1 | 2003 | 1620 | 0.120 |
Why?
|
Ibuprofen | 1 | 2016 | 236 | 0.120 |
Why?
|
Membrane Proteins | 1 | 2011 | 7880 | 0.120 |
Why?
|
Astrocytes | 1 | 2002 | 1270 | 0.120 |
Why?
|
Drug Approval | 3 | 2005 | 742 | 0.120 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3843 | 0.120 |
Why?
|
Risk Assessment | 5 | 2019 | 23338 | 0.120 |
Why?
|
Risk Factors | 9 | 2019 | 72290 | 0.120 |
Why?
|
Diffusion | 2 | 2008 | 833 | 0.120 |
Why?
|
Acupuncture Therapy | 1 | 2017 | 464 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 2 | 2020 | 738 | 0.110 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2016 | 365 | 0.110 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 1184 | 0.110 |
Why?
|
Tetrazolium Salts | 2 | 2009 | 96 | 0.110 |
Why?
|
Radiography | 3 | 2015 | 7023 | 0.110 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3133 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3240 | 0.100 |
Why?
|
Acetaminophen | 1 | 2016 | 545 | 0.100 |
Why?
|
Vascular Surgical Procedures | 2 | 2013 | 1475 | 0.100 |
Why?
|
Primary Prevention | 2 | 2018 | 1167 | 0.100 |
Why?
|
Registries | 3 | 2019 | 8089 | 0.100 |
Why?
|
Protein S Deficiency | 1 | 2010 | 16 | 0.100 |
Why?
|
Annexin A2 | 1 | 2011 | 44 | 0.100 |
Why?
|
Protein C Deficiency | 1 | 2010 | 29 | 0.100 |
Why?
|
Factor V Deficiency | 1 | 2010 | 13 | 0.100 |
Why?
|
Blood Pressure | 4 | 2017 | 8554 | 0.100 |
Why?
|
Antithrombin III Deficiency | 1 | 2010 | 30 | 0.100 |
Why?
|
Diffusion of Innovation | 1 | 2016 | 725 | 0.090 |
Why?
|
Perfusion | 2 | 2013 | 1360 | 0.090 |
Why?
|
Clinical Protocols | 1 | 2016 | 1462 | 0.090 |
Why?
|
Sensation Disorders | 2 | 2012 | 155 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8388 | 0.090 |
Why?
|
Fibrinolysis | 1 | 2011 | 322 | 0.090 |
Why?
|
Infrared Rays | 2 | 2009 | 249 | 0.090 |
Why?
|
Aged, 80 and over | 11 | 2020 | 57776 | 0.090 |
Why?
|
Rats, Inbred WKY | 3 | 2017 | 158 | 0.090 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2008 | 1518 | 0.080 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 1411 | 0.080 |
Why?
|
Neurons | 3 | 2011 | 9338 | 0.080 |
Why?
|
Cerebral Cortex | 1 | 2005 | 5708 | 0.080 |
Why?
|
Magnetic Field Therapy | 1 | 2008 | 28 | 0.080 |
Why?
|
Aged | 18 | 2020 | 163280 | 0.080 |
Why?
|
Checklist | 1 | 2015 | 833 | 0.080 |
Why?
|
Fibrin | 1 | 2011 | 506 | 0.080 |
Why?
|
Predictive Value of Tests | 3 | 2019 | 15076 | 0.080 |
Why?
|
Infusions, Intra-Arterial | 1 | 2008 | 234 | 0.080 |
Why?
|
Neuroradiography | 1 | 2008 | 70 | 0.080 |
Why?
|
Cell Death | 2 | 2011 | 1706 | 0.080 |
Why?
|
Diagnostic Imaging | 3 | 2008 | 3507 | 0.080 |
Why?
|
Hospital Units | 1 | 2009 | 141 | 0.080 |
Why?
|
Ganglia, Parasympathetic | 1 | 2007 | 19 | 0.080 |
Why?
|
Catheters | 1 | 2011 | 425 | 0.080 |
Why?
|
Cerebral Angiography | 2 | 2014 | 1285 | 0.080 |
Why?
|
Data Interpretation, Statistical | 2 | 2008 | 2716 | 0.080 |
Why?
|
United States | 11 | 2020 | 69872 | 0.080 |
Why?
|
Reproducibility of Results | 3 | 2019 | 19905 | 0.080 |
Why?
|
Fibrinogen | 1 | 2011 | 894 | 0.080 |
Why?
|
Hemodynamics | 1 | 2017 | 4199 | 0.070 |
Why?
|
Health Care Sector | 1 | 2009 | 194 | 0.070 |
Why?
|
Virginia | 1 | 2007 | 121 | 0.070 |
Why?
|
Health Priorities | 1 | 2010 | 380 | 0.070 |
Why?
|
Severity of Illness Index | 5 | 2009 | 15540 | 0.070 |
Why?
|
Software | 2 | 2019 | 4443 | 0.070 |
Why?
|
Middle Aged | 16 | 2019 | 213383 | 0.070 |
Why?
|
National Health Programs | 1 | 2010 | 445 | 0.070 |
Why?
|
Myocardial Reperfusion | 1 | 2008 | 351 | 0.070 |
Why?
|
Oxidative Stress | 1 | 2017 | 3086 | 0.070 |
Why?
|
Female | 21 | 2019 | 380194 | 0.070 |
Why?
|
Hospitals, University | 1 | 2008 | 571 | 0.070 |
Why?
|
Hypertension | 3 | 2017 | 8480 | 0.070 |
Why?
|
Guidelines as Topic | 2 | 2010 | 1405 | 0.070 |
Why?
|
Cortical Spreading Depression | 1 | 2009 | 276 | 0.070 |
Why?
|
Practice Guidelines as Topic | 2 | 2014 | 7279 | 0.060 |
Why?
|
World Health Organization | 2 | 2013 | 1318 | 0.060 |
Why?
|
Regional Blood Flow | 1 | 2008 | 1525 | 0.060 |
Why?
|
Language | 1 | 2014 | 1471 | 0.060 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 840 | 0.060 |
Why?
|
Species Specificity | 1 | 2009 | 2478 | 0.060 |
Why?
|
Double-Blind Method | 4 | 2017 | 12026 | 0.060 |
Why?
|
Peer Review, Research | 1 | 2007 | 329 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2007 | 780 | 0.060 |
Why?
|
Equipment Safety | 1 | 2005 | 264 | 0.060 |
Why?
|
Emergency Medical Services | 3 | 2020 | 1917 | 0.060 |
Why?
|
Stents | 1 | 2016 | 3280 | 0.060 |
Why?
|
Odds Ratio | 2 | 2007 | 9849 | 0.060 |
Why?
|
Databases, Factual | 2 | 2010 | 7729 | 0.060 |
Why?
|
Dipyridamole | 1 | 2003 | 145 | 0.060 |
Why?
|
Infusions, Intravenous | 1 | 2008 | 2274 | 0.060 |
Why?
|
Aorta | 1 | 2011 | 2061 | 0.060 |
Why?
|
Sample Size | 1 | 2006 | 845 | 0.060 |
Why?
|
Movement Disorders | 1 | 2006 | 445 | 0.050 |
Why?
|
Legislation, Drug | 1 | 2005 | 206 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2008 | 4933 | 0.050 |
Why?
|
Comprehension | 1 | 2008 | 610 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2006 | 841 | 0.050 |
Why?
|
Health Services Research | 1 | 2010 | 1836 | 0.050 |
Why?
|
Europe | 1 | 2009 | 3339 | 0.050 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2008 | 1240 | 0.050 |
Why?
|
Risk | 2 | 2005 | 9687 | 0.050 |
Why?
|
Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
Heptanoic Acids | 1 | 2004 | 343 | 0.050 |
Why?
|
Administration, Oral | 2 | 2020 | 3913 | 0.050 |
Why?
|
Brain Injuries | 1 | 2013 | 2025 | 0.050 |
Why?
|
Nervous System Diseases | 1 | 2012 | 1622 | 0.050 |
Why?
|
Boronic Acids | 1 | 2006 | 965 | 0.050 |
Why?
|
Recurrence | 3 | 2016 | 8340 | 0.050 |
Why?
|
Simvastatin | 1 | 2004 | 360 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2009 | 8949 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2020 | 77449 | 0.050 |
Why?
|
Carbon Dioxide | 1 | 2005 | 1150 | 0.050 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2005 | 430 | 0.050 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2005 | 2557 | 0.050 |
Why?
|
Equipment Design | 1 | 2008 | 3582 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5137 | 0.040 |
Why?
|
Patient Education as Topic | 1 | 2010 | 2278 | 0.040 |
Why?
|
Pyrazines | 1 | 2006 | 1230 | 0.040 |
Why?
|
Internet | 2 | 2010 | 3064 | 0.040 |
Why?
|
Politics | 1 | 2006 | 791 | 0.040 |
Why?
|
Internationality | 2 | 2020 | 1003 | 0.040 |
Why?
|
Drug Industry | 1 | 2005 | 746 | 0.040 |
Why?
|
Cognition Disorders | 1 | 2013 | 4043 | 0.040 |
Why?
|
Peptides | 1 | 2011 | 4409 | 0.040 |
Why?
|
Regression Analysis | 2 | 2008 | 6459 | 0.040 |
Why?
|
Models, Animal | 1 | 2005 | 2171 | 0.040 |
Why?
|
Drug Synergism | 1 | 2003 | 1792 | 0.040 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2019 | 170 | 0.040 |
Why?
|
Behavior, Animal | 1 | 2006 | 1881 | 0.040 |
Why?
|
Microscopy, Electron | 1 | 2002 | 2645 | 0.040 |
Why?
|
Drug Combinations | 1 | 2003 | 1959 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2007 | 2418 | 0.040 |
Why?
|
Videoconferencing | 1 | 2020 | 195 | 0.040 |
Why?
|
Health Care Surveys | 2 | 2019 | 2453 | 0.040 |
Why?
|
Rats, Inbred SHR | 1 | 2017 | 195 | 0.040 |
Why?
|
Collateral Circulation | 1 | 2019 | 287 | 0.040 |
Why?
|
Suture Techniques | 1 | 2003 | 798 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5391 | 0.040 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12245 | 0.040 |
Why?
|
Pyrroles | 1 | 2004 | 1146 | 0.040 |
Why?
|
Hypothalamus | 1 | 2003 | 1063 | 0.040 |
Why?
|
Image Enhancement | 1 | 2008 | 2921 | 0.040 |
Why?
|
Medicare | 3 | 2020 | 6566 | 0.040 |
Why?
|
Automation | 1 | 2019 | 584 | 0.040 |
Why?
|
United States Food and Drug Administration | 1 | 2005 | 1584 | 0.040 |
Why?
|
Urbanization | 1 | 2017 | 104 | 0.040 |
Why?
|
Treatment Failure | 1 | 2003 | 2618 | 0.040 |
Why?
|
Drug Substitution | 1 | 2019 | 281 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2005 | 1071 | 0.030 |
Why?
|
Teaching Rounds | 1 | 2020 | 253 | 0.030 |
Why?
|
Blood Glucose | 1 | 2010 | 6256 | 0.030 |
Why?
|
Electrocardiography | 1 | 2009 | 6442 | 0.030 |
Why?
|
Cells, Cultured | 1 | 2011 | 19229 | 0.030 |
Why?
|
Reference Values | 1 | 2003 | 4982 | 0.030 |
Why?
|
Water | 1 | 2002 | 1395 | 0.030 |
Why?
|
Sympathetic Nervous System | 1 | 2017 | 514 | 0.030 |
Why?
|
Antihypertensive Agents | 1 | 2004 | 2046 | 0.030 |
Why?
|
Skilled Nursing Facilities | 1 | 2018 | 372 | 0.030 |
Why?
|
Intracranial Aneurysm | 1 | 2004 | 1197 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2020 | 1681 | 0.030 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 670 | 0.030 |
Why?
|
Injections, Intra-Arterial | 1 | 2014 | 193 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2014 | 14722 | 0.030 |
Why?
|
Disaster Planning | 1 | 2020 | 549 | 0.030 |
Why?
|
Nursing Staff, Hospital | 1 | 2017 | 346 | 0.030 |
Why?
|
Health Resources | 1 | 2020 | 911 | 0.030 |
Why?
|
Filgrastim | 1 | 2013 | 133 | 0.030 |
Why?
|
Oxygen | 1 | 2005 | 4189 | 0.030 |
Why?
|
Cross-Sectional Studies | 2 | 2019 | 25043 | 0.030 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 12354 | 0.030 |
Why?
|
Patient Transfer | 1 | 2020 | 761 | 0.030 |
Why?
|
Prognosis | 3 | 2010 | 29063 | 0.030 |
Why?
|
Drug Utilization | 1 | 2019 | 1183 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2010 | 21746 | 0.030 |
Why?
|
Patient Admission | 1 | 2020 | 1380 | 0.030 |
Why?
|
Horner Syndrome | 1 | 2012 | 37 | 0.030 |
Why?
|
Postoperative Care | 1 | 2019 | 1486 | 0.030 |
Why?
|
Thromboembolism | 1 | 2018 | 986 | 0.030 |
Why?
|
Cardiac Surgical Procedures | 1 | 2007 | 3537 | 0.030 |
Why?
|
Thrombosis | 1 | 2006 | 2968 | 0.030 |
Why?
|
Hemiplegia | 1 | 2012 | 135 | 0.030 |
Why?
|
Fear | 1 | 2020 | 1440 | 0.020 |
Why?
|
Brain Mapping | 1 | 2007 | 6669 | 0.020 |
Why?
|
Prospective Studies | 3 | 2017 | 53288 | 0.020 |
Why?
|
Ophthalmoplegia | 1 | 2012 | 166 | 0.020 |
Why?
|
Cohort Studies | 3 | 2020 | 40561 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2003 | 8642 | 0.020 |
Why?
|
Hemianopsia | 1 | 2012 | 122 | 0.020 |
Why?
|
Paralysis | 1 | 2012 | 247 | 0.020 |
Why?
|
Glasgow Coma Scale | 1 | 2012 | 570 | 0.020 |
Why?
|
Adult | 7 | 2019 | 214055 | 0.020 |
Why?
|
Decision Making | 1 | 2004 | 3887 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2017 | 2077 | 0.020 |
Why?
|
Preoperative Care | 1 | 2019 | 2250 | 0.020 |
Why?
|
Antioxidants | 1 | 2017 | 1663 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1056 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1654 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2020 | 2708 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2009 | 187 | 0.020 |
Why?
|
Organizational Objectives | 1 | 2010 | 438 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2008 | 159 | 0.020 |
Why?
|
Technology | 1 | 2010 | 305 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2020 | 3589 | 0.020 |
Why?
|
Health Promotion | 1 | 2020 | 2205 | 0.020 |
Why?
|
Single-Blind Method | 1 | 2011 | 1590 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5952 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3022 | 0.020 |
Why?
|
Quality of Life | 1 | 2007 | 12804 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6895 | 0.020 |
Why?
|
Databases as Topic | 1 | 2008 | 475 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6538 | 0.020 |
Why?
|
Brain Damage, Chronic | 1 | 2006 | 265 | 0.020 |
Why?
|
Catheterization | 1 | 2011 | 1470 | 0.020 |
Why?
|
Streptokinase | 1 | 2005 | 188 | 0.020 |
Why?
|
Hypercapnia | 1 | 2006 | 260 | 0.020 |
Why?
|
Perceptual Disorders | 1 | 2006 | 196 | 0.020 |
Why?
|
Mice | 1 | 2011 | 81183 | 0.020 |
Why?
|
Health Education | 1 | 2010 | 1056 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2005 | 39050 | 0.010 |
Why?
|
History, 20th Century | 1 | 2010 | 2740 | 0.010 |
Why?
|
Expert Testimony | 1 | 2005 | 356 | 0.010 |
Why?
|
Societies, Medical | 1 | 2014 | 3743 | 0.010 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2005 | 641 | 0.010 |
Why?
|
Benchmarking | 1 | 2008 | 1042 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2008 | 2715 | 0.010 |
Why?
|
Emergency Service, Hospital | 1 | 2020 | 7659 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 6993 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2005 | 1344 | 0.010 |
Why?
|
Internship and Residency | 1 | 2020 | 5788 | 0.010 |
Why?
|
Reaction Time | 1 | 2006 | 2097 | 0.010 |
Why?
|
Health Policy | 1 | 2010 | 2661 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2008 | 2266 | 0.010 |
Why?
|
Public Health | 1 | 2010 | 2603 | 0.010 |
Why?
|
Phenotype | 1 | 2013 | 16365 | 0.010 |
Why?
|
Signal Transduction | 1 | 2017 | 23403 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2008 | 5317 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10943 | 0.010 |
Why?
|
Survival Analysis | 1 | 2004 | 10252 | 0.010 |
Why?
|
Young Adult | 1 | 2012 | 56430 | 0.000 |
Why?
|
Adolescent | 1 | 2013 | 85781 | 0.000 |
Why?
|